Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd_task_9aae8fc5",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "# Feasibility Assessment: ALS Neuron-Specific Autophagy Hypotheses\n\n---\n\n## Summary Comparison Matrix\n\n| Domain | H1: Axonal Transport (C9orf72/RAB7) | H2: OPTN/TBK1 Mitophagy | H3: TDP-43 SNARE Fusion | H4: VCP Crosstalk |\n|--------|-------------------------------------|-------------------------|-------------------------|-------------------|\n| **Confidence** | 0.62 | 0.58 | 0.52 | ~0.55 (est.) |\n| **Druggability** | Low-Moderate | Moderate-High | Low | High |\n| **Biomarker Readiness** | Moderate | Moderate | Low-Moderate | Moderate |\n| **Model Systems** | Strong (iPSC MN) | Moderate | Weak | Moderate |\n| **Safety Risk** | High | Moderate-High | Moderate | High |\n| **Timeline** | Long (>10 yrs) | Medium-Long (7-10 yrs) | Long (>12 yrs) | Medium (5-8 yrs) |\n| **Estimated Cost** | Very High | High | Very High | High |\n| **Overall Feasibility** | **Moderate-Low** | **Moderate** | **Low** | **Moderate** |\n\n---\n\n## Hypothesis 1: Axonal Transport Defect (C9orf72/RAB7/Dynein)\n\n### Druggability: LOW-MODERATE\n- **Primary target (dynein-dynactin)** is a megadalton motor complex with no known small molecule agonists; only inhibitors exist (dynein inhibitors like Ciliobrevin D are research tools, not therapeutics)\n- **RAB7A** is more tractable but requires GTPase activation (not just inhibition), an underexplored pharmacology space\n- **C9orf72 function restoration** is indirect and mechanistically ambiguous—is mechanism haploinsufficiency or gain-of-toxicity?\n- **Delivery challenge**: Motor neuron-targeted delivery across the blood-brain barrier remains unsolved\n\n**Most tractable entry point**: RAB7 nucleotide exchange factors (DENN-domain proteins) as activators—no validated agonists exist but protein-protein interaction modulators are emerging\n\n### Biomarkers/Model Systems: MODERATE\n- **Strong model systems**: iPSC-derived motor neurons with live-cell axonal transport assays in microfluidic chambers are well-established and translatable\n- **Biomarker candidates**: Axonal degeneration markers (NfL, NfH in CSF/plasma), but none specific to transport defects vs. general neurodegeneration\n- **Autophagy flux reporters** (mCherry-eGFP-LC3) work but require invasive sampling\n- **Imaging-based biomarkers**: PET tracers for autophagosome accumulation do not exist; super-resolution microscopy needed for mechanistic validation in human tissue\n\n**Validation gap**: No validated blood/CSF biomarker distinguishes transport defects from other ALS autophagy mechanisms\n\n### Clinical Development Constraints\n- **Patient stratification**: C9orf72 expansion carriers represent ~40% of familial ALS, but mechanistic heterogeneity within this group is substantial\n- **Target engagement assays**: Axonal transport in living patients is not measurable; must rely on surrogate endpoints (NfL trajectory, functional scores)\n- **Combination approach likely needed**: Pure transport modulation unlikely to overcome polyglutamine/dipeptide repeat toxicity from the same mutation\n- **Regulatory path**: ALS indication with validated enrichment for C9orf72 patients is acceptable; primary endpoint would likely be survival or functional decline (ALSF",
  "tokens_used": "788",
  "persona_id": "persona-domain_expert"
}